NATCO
GenericsNATCO is a generic drug manufacturer focused on Oncology, Infectious Disease, Neurology. Key products include LAMIVUDINE AND ZIDOVUDINE.
NATCO's Key Drugs
NATCO's core commercial portfolio centers on TELMISARTAN AND HYDROCHLOROTHIAZIDE, TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE, spanning Oncology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
NATCO's Recent FDA Approvals
New NDA/BLA approvals for NATCO over the last two years — novel drugs only, excluding generics and label supplements.
NATCO's Therapeutic Areas
NATCO's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NATCO's Top Competitors
NATCO's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Bristol-Myers Squibb, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NATCO Pipeline Snapshot
NATCO has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TELMISARTAN AND HYDROCHLOROTHIAZIDE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (1)
Company Info
- First Approval
- 1986-03-21
- Latest
- 2026-06-01
- Applications
- 25